Regulatory Expectations Regarding KRIs

Published on 22/12/2025

What Do Regulatory Authorities Expect from Your KRI Framework?

Table of Contents

Introduction: KRIs in the Eyes of Regulators

As Risk-Based Monitoring (RBM) becomes standard practice in clinical trials, the use of Key Risk Indicators (KRIs) has drawn the attention of regulators worldwide. Whether it’s the FDA, EMA, or PMDA, authorities want assurance that sponsors are actively identifying, monitoring, and responding to trial risks in real time. KRIs form a core part of this risk detection framework.

Regulators expect not just the existence of KRIs, but structured processes around their definition, thresholds, response mechanisms, and documentation. Their use must align with Good Clinical Practice (GCP) principles and quality risk management (QRM) plans. In this article, we examine what regulators look for when reviewing your KRI system and how to remain compliant.

Regulatory Foundations: ICH E6(R2) and Beyond

The foundation of regulatory expectations lies in ICH E6(R2), which mandates that sponsors implement a risk-based approach to monitoring. The guideline specifically recommends using “centralized monitoring processes” and “targeted monitoring activities”—both of which rely on KRIs.

Key points from ICH E6(R2):

Critical processes and data must be identified and monitored continuously
Risks must be assessed, controlled, communicated, and reviewed regularly
Monitoring methods should be proportionate to risk and

complexity

KRIs serve as quantifiable metrics aligned with these objectives. Visit ICH E6(R2) for the full guidance text.

FDA Expectations on KRIs in RBM

The FDA’s 2013 guidance on RBM and their Bioresearch Monitoring Program make it clear that sponsors are expected to:

Identify trial-specific risks early
Define KRIs and link them to monitoring strategies
Track deviations, delays, and data anomalies through defined metrics
Document all monitoring actions triggered by KRI thresholds

For example, if the deviation rate crosses a threshold and triggers a monitoring visit, the justification, findings, and CAPA must be traceable. During BIMO inspections, KRIs are often reviewed through Monitoring Plans and CTMS audit trails. Read more at the FDA RBM guidance.

EMA Perspective and Reflection Paper Insights

The EMA’s 2013 Reflection Paper emphasizes continuous quality improvement and risk control. Although it doesn’t list specific KRIs, it expects sponsors to:

Embed KRIs in the Quality Management System (QMS)
Use them to monitor protocol adherence, safety reporting, and data integrity
Document thresholds and risk scores in monitoring systems
Define actions to be taken for KRI breaches

Failure to justify monitoring decisions using KRI trends may be cited during inspections. European inspectors often request evidence of trend analysis, dashboard reviews, and CRA escalations linked to KRIs.

Common Documentation Requirements

Authorities expect sponsors to have complete documentation around KRIs. Key documents include:

Monitoring Plan: List of selected KRIs, thresholds, and escalation paths
QRM Plan: Mapping of risks to KRIs and control measures
SOPs: Detailing how KRIs are defined, tracked, and acted upon
Audit Trail: Logs of dashboard reviews, threshold breaches, and corrective actions
Inspection Readiness Folder: Screenshots, logs, and examples of KRI-based oversight

For a sample KRI Monitoring SOP and deviation response templates, see PharmaSOP.

Threshold Justification and Risk Categorization

Merely setting a KRI threshold is not sufficient—regulators expect a rationale. For instance:

Why was the SAE reporting delay set at 48 hours instead of 72?
How was the deviation rate of 1.5 per subject decided?
What risk level is associated with each color band (green/yellow/red)?

Documented justification for each threshold must be based on protocol complexity, therapeutic area, and past trial benchmarks. Some sponsors use statistical process control (SPC) charts or percentile-based cutoffs for evidence-based thresholding.

Case Study: Inspection Finding Due to Inadequate KRI Response

In a 2022 EMA inspection of a Phase 2 oncology study, the sponsor received a major finding because:

The protocol deviation rate at one site exceeded the threshold for three months
No additional monitoring or CRA follow-up was triggered
The threshold breach was visible on the dashboard but not reviewed or acted upon
No CAPA was initiated despite evidence of continued violations

This example underscores the importance of not just tracking KRIs but closing the loop with documented action. Refer to PharmaValidation for validation guidance and audit checklists.

Best Practices for Regulatory-Ready KRI Systems

Predefine KRI thresholds in Monitoring Plans and justify them in the QRM Plan
Integrate KRI review logs into TMF and CTMS with timestamps and signatures
Train CRAs and Central Monitors on interpretation and response workflows
Ensure dashboards are validated and updates are version-controlled
Include periodic review of KRIs and thresholds during TMF QC or QMS review

A mature KRI program is a major asset during inspections, demonstrating proactive oversight and quality culture.

Conclusion

Regulators expect KRIs to be more than just colorful dashboards—they must be functional tools embedded in the monitoring lifecycle. From threshold justification to escalation workflows and documentation trails, sponsors must show that KRIs actively inform and drive risk-based decisions. Aligning your KRI practices with ICH, FDA, and EMA expectations ensures both compliance and operational excellence.